 | • レポートコード：MRC2-11QY04963 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は子宮筋腫のグローバル市場について調査・分析したレポートです。種類別（非ホルモン療法、ホルモン療法）市場規模、用途別（病院、外来外科センター、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別子宮筋腫の競争状況、市場シェア ・世界の子宮筋腫市場：種類別市場規模 2015年-2020年（非ホルモン療法、ホルモン療法） ・世界の子宮筋腫市場：種類別市場規模予測 2021年-2026年（非ホルモン療法、ホルモン療法） ・世界の子宮筋腫市場：用途別市場規模 2015年-2020年（病院、外来外科センター、診断センター、その他） ・世界の子宮筋腫市場：用途別市場規模予測 2021年-2026年（病院、外来外科センター、診断センター、その他） ・北米の子宮筋腫市場分析：米国、カナダ ・ヨーロッパの子宮筋腫市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの子宮筋腫市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の子宮筋腫市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの子宮筋腫市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Boston Scientific、Cooper Surgical、C.R. Bard、F. Hoffmann-La Roche、GE Healthcare、Karl Storz Endoscopy、Richard Wolf Medical Instruments、Siemens Medical Solutions、AbbVie、AstraZeneca、Bayer、Eli Lilly、GlaxoSmithKline Pharmaceuticals、Pfizer、Johnson & Johnson、Novartis ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Uterine fibroids (myoma) are benign (non-cancerous) lumps that grow in the muscular wall of the uterus. They vary in sizes, from minute (a quarter of an inch) to the size of more than16 centimeters. The incidence of uterine fibroid is about 20%–40% in women during their reproductive ages. Occasionally, these fibroids swell up and make the uterus to grow like full visible pregnancy. Mostly, there are more than one fibroid in the uterus. However, fibroids do not always cause any symptoms, their location, and size results to difficulties for few women, including pain, discomfort and heavy bleeding. Uterine fibroid can be of different types such as intramural fibroids, subserosal fibroids, pedunculated fibroids and submucosal fibroids. There can be many reasons for uterine fibroid formation but genetic problems hormonal imbalance and other factors are predominant. The cardinal symptoms of uterine fibroids are heavy menstrual bleeding, abdominal pain, excessive uterine bleeding, increased urinary frequency, anaemia and infertility. Apart from physical morbidity, uterine fibroid ailment is a frequent cause of significant damage of quality of life and a major reason for hysterectomy. Therapy has traditionally based on two extremes: medicinal management, comprising progestins, oral contraceptives and GnRH agonists and surgical management, including myomectomy, hysterectomy, and ablation for most serious cases.
Patients suffering from uterine fibroid problem represent an undeserved and huge market due to the absence of satisfactory medical treatments. Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.
Market Analysis and Insights: Global Uterine Fibroids Market
The global Uterine Fibroids market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Uterine Fibroids Scope and Market Size
Uterine Fibroids market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Fibroids market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Boston Scientific
Cooper Surgical
C.R. Bard
F. Hoffmann-La Roche
GE Healthcare
Karl Storz Endoscopy
Richard Wolf Medical Instruments
Siemens Medical Solutions
AbbVie
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline Pharmaceuticals
Pfizer
Johnson & Johnson
Novartis
Market segment by Type, the product can be split into
Non-Hormonal Treatment
Hormonal Treatment
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Uterine Fibroids Revenue
1.4 Market by Type
1.4.1 Global Uterine Fibroids Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Non-Hormonal Treatment
1.4.3 Hormonal Treatment
1.5 Market by Application
1.5.1 Global Uterine Fibroids Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Diagnostic Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Uterine Fibroids Market Perspective (2015-2026)
2.2 Global Uterine Fibroids Growth Trends by Regions
2.2.1 Uterine Fibroids Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Uterine Fibroids Historic Market Share by Regions (2015-2020)
2.2.3 Uterine Fibroids Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Uterine Fibroids Market Growth Strategy
2.3.6 Primary Interviews with Key Uterine Fibroids Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Uterine Fibroids Players by Market Size
3.1.1 Global Top Uterine Fibroids Players by Revenue (2015-2020)
3.1.2 Global Uterine Fibroids Revenue Market Share by Players (2015-2020)
3.1.3 Global Uterine Fibroids Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Uterine Fibroids Market Concentration Ratio
3.2.1 Global Uterine Fibroids Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Uterine Fibroids Revenue in 2019
3.3 Uterine Fibroids Key Players Head office and Area Served
3.4 Key Players Uterine Fibroids Product Solution and Service
3.5 Date of Enter into Uterine Fibroids Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Uterine Fibroids Historic Market Size by Type (2015-2020)
4.2 Global Uterine Fibroids Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Uterine Fibroids Market Size by Application (2015-2020)
5.2 Global Uterine Fibroids Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Uterine Fibroids Market Size (2015-2020)
6.2 Uterine Fibroids Key Players in North America (2019-2020)
6.3 North America Uterine Fibroids Market Size by Type (2015-2020)
6.4 North America Uterine Fibroids Market Size by Application (2015-2020)
7 Europe
7.1 Europe Uterine Fibroids Market Size (2015-2020)
7.2 Uterine Fibroids Key Players in Europe (2019-2020)
7.3 Europe Uterine Fibroids Market Size by Type (2015-2020)
7.4 Europe Uterine Fibroids Market Size by Application (2015-2020)
8 China
8.1 China Uterine Fibroids Market Size (2015-2020)
8.2 Uterine Fibroids Key Players in China (2019-2020)
8.3 China Uterine Fibroids Market Size by Type (2015-2020)
8.4 China Uterine Fibroids Market Size by Application (2015-2020)
9 Japan
9.1 Japan Uterine Fibroids Market Size (2015-2020)
9.2 Uterine Fibroids Key Players in Japan (2019-2020)
9.3 Japan Uterine Fibroids Market Size by Type (2015-2020)
9.4 Japan Uterine Fibroids Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Uterine Fibroids Market Size (2015-2020)
10.2 Uterine Fibroids Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Uterine Fibroids Market Size by Type (2015-2020)
10.4 Southeast Asia Uterine Fibroids Market Size by Application (2015-2020)
11 India
11.1 India Uterine Fibroids Market Size (2015-2020)
11.2 Uterine Fibroids Key Players in India (2019-2020)
11.3 India Uterine Fibroids Market Size by Type (2015-2020)
11.4 India Uterine Fibroids Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Uterine Fibroids Market Size (2015-2020)
12.2 Uterine Fibroids Key Players in Central & South America (2019-2020)
12.3 Central & South America Uterine Fibroids Market Size by Type (2015-2020)
12.4 Central & South America Uterine Fibroids Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Boston Scientific
13.1.1 Boston Scientific Company Details
13.1.2 Boston Scientific Business Overview
13.1.3 Boston Scientific Uterine Fibroids Introduction
13.1.4 Boston Scientific Revenue in Uterine Fibroids Business (2015-2020))
13.1.5 Boston Scientific Recent Development
13.2 Cooper Surgical
13.2.1 Cooper Surgical Company Details
13.2.2 Cooper Surgical Business Overview
13.2.3 Cooper Surgical Uterine Fibroids Introduction
13.2.4 Cooper Surgical Revenue in Uterine Fibroids Business (2015-2020)
13.2.5 Cooper Surgical Recent Development
13.3 C.R. Bard
13.3.1 C.R. Bard Company Details
13.3.2 C.R. Bard Business Overview
13.3.3 C.R. Bard Uterine Fibroids Introduction
13.3.4 C.R. Bard Revenue in Uterine Fibroids Business (2015-2020)
13.3.5 C.R. Bard Recent Development
13.4 F. Hoffmann-La Roche
13.4.1 F. Hoffmann-La Roche Company Details
13.4.2 F. Hoffmann-La Roche Business Overview
13.4.3 F. Hoffmann-La Roche Uterine Fibroids Introduction
13.4.4 F. Hoffmann-La Roche Revenue in Uterine Fibroids Business (2015-2020)
13.4.5 F. Hoffmann-La Roche Recent Development
13.5 GE Healthcare
13.5.1 GE Healthcare Company Details
13.5.2 GE Healthcare Business Overview
13.5.3 GE Healthcare Uterine Fibroids Introduction
13.5.4 GE Healthcare Revenue in Uterine Fibroids Business (2015-2020)
13.5.5 GE Healthcare Recent Development
13.6 Karl Storz Endoscopy
13.6.1 Karl Storz Endoscopy Company Details
13.6.2 Karl Storz Endoscopy Business Overview
13.6.3 Karl Storz Endoscopy Uterine Fibroids Introduction
13.6.4 Karl Storz Endoscopy Revenue in Uterine Fibroids Business (2015-2020)
13.6.5 Karl Storz Endoscopy Recent Development
13.7 Richard Wolf Medical Instruments
13.7.1 Richard Wolf Medical Instruments Company Details
13.7.2 Richard Wolf Medical Instruments Business Overview
13.7.3 Richard Wolf Medical Instruments Uterine Fibroids Introduction
13.7.4 Richard Wolf Medical Instruments Revenue in Uterine Fibroids Business (2015-2020)
13.7.5 Richard Wolf Medical Instruments Recent Development
13.8 Siemens Medical Solutions
13.8.1 Siemens Medical Solutions Company Details
13.8.2 Siemens Medical Solutions Business Overview
13.8.3 Siemens Medical Solutions Uterine Fibroids Introduction
13.8.4 Siemens Medical Solutions Revenue in Uterine Fibroids Business (2015-2020)
13.8.5 Siemens Medical Solutions Recent Development
13.9 AbbVie
13.9.1 AbbVie Company Details
13.9.2 AbbVie Business Overview
13.9.3 AbbVie Uterine Fibroids Introduction
13.9.4 AbbVie Revenue in Uterine Fibroids Business (2015-2020)
13.9.5 AbbVie Recent Development
13.10 AstraZeneca
13.10.1 AstraZeneca Company Details
13.10.2 AstraZeneca Business Overview
13.10.3 AstraZeneca Uterine Fibroids Introduction
13.10.4 AstraZeneca Revenue in Uterine Fibroids Business (2015-2020)
13.10.5 AstraZeneca Recent Development
13.11 Bayer
10.11.1 Bayer Company Details
10.11.2 Bayer Business Overview
10.11.3 Bayer Uterine Fibroids Introduction
10.11.4 Bayer Revenue in Uterine Fibroids Business (2015-2020)
10.11.5 Bayer Recent Development
13.12 Eli Lilly
10.12.1 Eli Lilly Company Details
10.12.2 Eli Lilly Business Overview
10.12.3 Eli Lilly Uterine Fibroids Introduction
10.12.4 Eli Lilly Revenue in Uterine Fibroids Business (2015-2020)
10.12.5 Eli Lilly Recent Development
13.13 GlaxoSmithKline Pharmaceuticals
10.13.1 GlaxoSmithKline Pharmaceuticals Company Details
10.13.2 GlaxoSmithKline Pharmaceuticals Business Overview
10.13.3 GlaxoSmithKline Pharmaceuticals Uterine Fibroids Introduction
10.13.4 GlaxoSmithKline Pharmaceuticals Revenue in Uterine Fibroids Business (2015-2020)
10.13.5 GlaxoSmithKline Pharmaceuticals Recent Development
13.14 Pfizer
10.14.1 Pfizer Company Details
10.14.2 Pfizer Business Overview
10.14.3 Pfizer Uterine Fibroids Introduction
10.14.4 Pfizer Revenue in Uterine Fibroids Business (2015-2020)
10.14.5 Pfizer Recent Development
13.15 Johnson & Johnson
10.15.1 Johnson & Johnson Company Details
10.15.2 Johnson & Johnson Business Overview
10.15.3 Johnson & Johnson Uterine Fibroids Introduction
10.15.4 Johnson & Johnson Revenue in Uterine Fibroids Business (2015-2020)
10.15.5 Johnson & Johnson Recent Development
13.16 Novartis
10.16.1 Novartis Company Details
10.16.2 Novartis Business Overview
10.16.3 Novartis Uterine Fibroids Introduction
10.16.4 Novartis Revenue in Uterine Fibroids Business (2015-2020)
10.16.5 Novartis Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Uterine Fibroids Key Market Segments
Table 2. Key Players Covered: Ranking by Uterine Fibroids Revenue
Table 3. Ranking of Global Top Uterine Fibroids Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Uterine Fibroids Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Non-Hormonal Treatment
Table 6. Key Players of Hormonal Treatment
Table 7. Global Uterine Fibroids Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Uterine Fibroids Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Uterine Fibroids Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Uterine Fibroids Market Share by Regions (2015-2020)
Table 11. Global Uterine Fibroids Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Uterine Fibroids Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Uterine Fibroids Market Growth Strategy
Table 17. Main Points Interviewed from Key Uterine Fibroids Players
Table 18. Global Uterine Fibroids Revenue by Players (2015-2020) (Million US$)
Table 19. Global Uterine Fibroids Market Share by Players (2015-2020)
Table 20. Global Top Uterine Fibroids Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Fibroids as of 2019)
Table 21. Global Uterine Fibroids by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Uterine Fibroids Product Solution and Service
Table 24. Date of Enter into Uterine Fibroids Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 27. Global Uterine Fibroids Market Size Share by Type (2015-2020)
Table 28. Global Uterine Fibroids Revenue Market Share by Type (2021-2026)
Table 29. Global Uterine Fibroids Market Size Share by Application (2015-2020)
Table 30. Global Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 31. Global Uterine Fibroids Market Size Share by Application (2021-2026)
Table 32. North America Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Uterine Fibroids Market Share (2019-2020)
Table 34. North America Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 35. North America Uterine Fibroids Market Share by Type (2015-2020)
Table 36. North America Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 37. North America Uterine Fibroids Market Share by Application (2015-2020)
Table 38. Europe Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Uterine Fibroids Market Share (2019-2020)
Table 40. Europe Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Uterine Fibroids Market Share by Type (2015-2020)
Table 42. Europe Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Uterine Fibroids Market Share by Application (2015-2020)
Table 44. China Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 45. China Key Players Uterine Fibroids Market Share (2019-2020)
Table 46. China Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 47. China Uterine Fibroids Market Share by Type (2015-2020)
Table 48. China Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 49. China Uterine Fibroids Market Share by Application (2015-2020)
Table 50. Japan Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Uterine Fibroids Market Share (2019-2020)
Table 52. Japan Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Uterine Fibroids Market Share by Type (2015-2020)
Table 54. Japan Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Uterine Fibroids Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Uterine Fibroids Market Share (2019-2020)
Table 58. Southeast Asia Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Uterine Fibroids Market Share by Type (2015-2020)
Table 60. Southeast Asia Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Uterine Fibroids Market Share by Application (2015-2020)
Table 62. India Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 63. India Key Players Uterine Fibroids Market Share (2019-2020)
Table 64. India Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 65. India Uterine Fibroids Market Share by Type (2015-2020)
Table 66. India Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 67. India Uterine Fibroids Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Uterine Fibroids Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Uterine Fibroids Market Share (2019-2020)
Table 70. Central & South America Uterine Fibroids Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Uterine Fibroids Market Share by Type (2015-2020)
Table 72. Central & South America Uterine Fibroids Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Uterine Fibroids Market Share by Application (2015-2020)
Table 74. Boston Scientific Company Details
Table 75. Boston Scientific Business Overview
Table 76. Boston Scientific Product
Table 77. Boston Scientific Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 78. Boston Scientific Recent Development
Table 79. Cooper Surgical Company Details
Table 80. Cooper Surgical Business Overview
Table 81. Cooper Surgical Product
Table 82. Cooper Surgical Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 83. Cooper Surgical Recent Development
Table 84. C.R. Bard Company Details
Table 85. C.R. Bard Business Overview
Table 86. C.R. Bard Product
Table 87. C.R. Bard Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 88. C.R. Bard Recent Development
Table 89. F. Hoffmann-La Roche Company Details
Table 90. F. Hoffmann-La Roche Business Overview
Table 91. F. Hoffmann-La Roche Product
Table 92. F. Hoffmann-La Roche Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 93. F. Hoffmann-La Roche Recent Development
Table 94. GE Healthcare Company Details
Table 95. GE Healthcare Business Overview
Table 96. GE Healthcare Product
Table 97. GE Healthcare Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 98. GE Healthcare Recent Development
Table 99. Karl Storz Endoscopy Company Details
Table 100. Karl Storz Endoscopy Business Overview
Table 101. Karl Storz Endoscopy Product
Table 102. Karl Storz Endoscopy Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 103. Karl Storz Endoscopy Recent Development
Table 104. Richard Wolf Medical Instruments Company Details
Table 105. Richard Wolf Medical Instruments Business Overview
Table 106. Richard Wolf Medical Instruments Product
Table 107. Richard Wolf Medical Instruments Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 108. Richard Wolf Medical Instruments Recent Development
Table 109. Siemens Medical Solutions Business Overview
Table 110. Siemens Medical Solutions Product
Table 111. Siemens Medical Solutions Company Details
Table 112. Siemens Medical Solutions Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 113. Siemens Medical Solutions Recent Development
Table 114. AbbVie Company Details
Table 115. AbbVie Business Overview
Table 116. AbbVie Product
Table 117. AbbVie Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 118. AbbVie Recent Development
Table 119. AstraZeneca Company Details
Table 120. AstraZeneca Business Overview
Table 121. AstraZeneca Product
Table 122. AstraZeneca Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 123. AstraZeneca Recent Development
Table 124. Bayer Company Details
Table 125. Bayer Business Overview
Table 126. Bayer Product
Table 127. Bayer Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 128. Bayer Recent Development
Table 129. Eli Lilly Company Details
Table 130. Eli Lilly Business Overview
Table 131. Eli Lilly Product
Table 132. Eli Lilly Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 133. Eli Lilly Recent Development
Table 134. GlaxoSmithKline Pharmaceuticals Company Details
Table 135. GlaxoSmithKline Pharmaceuticals Business Overview
Table 136. GlaxoSmithKline Pharmaceuticals Product
Table 137. GlaxoSmithKline Pharmaceuticals Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 138. GlaxoSmithKline Pharmaceuticals Recent Development
Table 139. Pfizer Company Details
Table 140. Pfizer Business Overview
Table 141. Pfizer Product
Table 142. Pfizer Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 143. Pfizer Recent Development
Table 144. Johnson & Johnson Company Details
Table 145. Johnson & Johnson Business Overview
Table 146. Johnson & Johnson Product
Table 147. Johnson & Johnson Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 148. Johnson & Johnson Recent Development
Table 149. Novartis Company Details
Table 150. Novartis Business Overview
Table 151. Novartis Product
Table 152. Novartis Revenue in Uterine Fibroids Business (2015-2020) (Million US$)
Table 153. Novartis Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Uterine Fibroids Market Share by Type: 2020 VS 2026
Figure 2. Non-Hormonal Treatment Features
Figure 3. Hormonal Treatment Features
Figure 4. Global Uterine Fibroids Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Ambulatory Surgical Centers Case Studies
Figure 7. Diagnostic Centers Case Studies
Figure 8. Others Case Studies
Figure 9. Uterine Fibroids Report Years Considered
Figure 10. Global Uterine Fibroids Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Uterine Fibroids Market Share by Regions: 2020 VS 2026
Figure 12. Global Uterine Fibroids Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Uterine Fibroids Market Share by Players in 2019
Figure 15. Global Top Uterine Fibroids Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Uterine Fibroids as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Uterine Fibroids Revenue in 2019
Figure 17. North America Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Uterine Fibroids Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
子宮筋腫治療薬の世界市場（～2026年） Uterine fibroids are the most common benign tumors in female reproductive organs and one of the most common tumors in human body. They are mainly caused by proliferation of uterine smooth muscle cells. Market Analysis and Insights: Global Uterine Fibroids Drug Market The global Uterine Fibroids Drug…- 子宮がん診断検査の世界市場（～2026年） Uterus a female organ also referred as the womb is located in the lower abdomen. It supports in the fetal development until birth. In North America, the U.S. is expected to be the dominant market for uterine cancer diagnostic testing due to growing incidence of uterine cancer. Market Analysis and In…
- 子宮筋腫治療装置の世界市場（～2026年） Uterine fibroids are noncancerous growths of the uterus that often appear during childbearing years. Also called leiomyomas (lie-o-my-O-muhs) or myomas, uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer. Market Analysis and Insights: Glo…
- 子宮疾患治療薬の世界市場（～2026年） Uterus is the muscle organ in female reproductive system, which plays a great role in female reproduction and fetal development. The incidence of uterine diseases is also very high, so the treatment of uterine diseases is particularly important. Market Analysis and Insights: Global Uterine Diseases …
- 子宮内膜ポリープ治療薬の世界市場（～2026年） Uterine polyps are common gynecological diseases. Broadly speaking, it refers to all tumors attached to the uterine wall by slender pedicle. Mostly benign. Market Analysis and Insights: Global Uterine Polyps Drug Market The global Uterine Polyps Drug market size is projected to reach US$ XX million …